Mitochondrial peptides: state of the evidence in 2026

The mitochondrial peptide field has matured substantially over the past decade. Three compounds now dominate the literature: Humanin (discovered 2001, encoded in the mitochondrial 16S rRNA gene), MOTS-c (discovered 2015, encoded in the 12S rRNA gene) and SS-31 (synthetic Szeto-Schiller cardiolipin stabiliser, designed in the early 2000s).

Humanin's profile is increasingly that of an endocrine mitokine — a peptide released by mitochondria under stress that signals systemically to coordinate cellular and metabolic adaptation. The 2014 Yen et al. paper linking plasma Humanin to longevity in centenarian offspring positioned the peptide squarely within ageing biology, and subsequent work has supported the framing.

MOTS-c has accumulated a coherent body of evidence for its role as an endogenous exercise-mimetic, with the Reynolds et al. 2021 Nature Communications paper providing the most comprehensive demonstration of partial exercise-pathway reproduction in aged muscle. The 2018 Kim et al. demonstration of nuclear translocation and chromatin binding under stress placed MOTS-c among the small set of peptides with documented direct gene-regulatory activity.

SS-31 has the most-developed clinical-translation programme. Phase II and III trials in primary mitochondrial myopathy (MMPOWER), dry AMD (ReCLAIM) and ischaemia-reperfusion contexts have produced mixed efficacy outcomes but a strong human safety dataset. The Siegel et al. 2013 paper demonstrating restoration of aged-muscle physical performance to young-mouse levels within 8 days remains one of the most striking proof-of-mechanism observations in the longevity literature.

The integrative question for 2026 is whether mitochondrial peptide combinations — signalling mitokines paired with structural stabilisers — produce additive or synergistic effects. The mechanistic case is plausible; clinical data has not yet tested it.